Provisions for Drug Advertisement Examination

作者:法律资料网 时间:2024-07-11 12:48:40   浏览:9498   来源:法律资料网
下载地址: 点击此处下载

Provisions for Drug Advertisement Examination

State Food and Drug Administration,State Administration for Industry and Commerceof the People’s Republic of China


Provisions for Drug Advertisement Examination



(SFDA Decree No. 27)

The Provisions for Drug Advertisement Examination, adopted by the State Food and Drug Administration and the State Administration for Industry and Commerce of the People’s Republic of China, is now issued in the decree sequence number of the State Food and Drug Administration. The Provisions shall go into effect as of the date of May 1, 2007.



Shao Mingli
Commissioner
State Food and Drug Administration

Zhou Bohua
Minister
State Administration for Industry and Commerceof the People’s Republic of China

March 13, 2007





Provisions for Drug Advertisement Examination


Article 1 The Provisions are formulated for the purposes of strengthening regulation on drug advertisements and ensuring the authenticity and legality of drug advertisements in accordance with the Advertisement Law of the People’s Republic of China (hereinafter referred to as Advertisement Law), the Drug Administration Law of the People's Republic of China (hereinafter referred to as Drug Administration Law), the Regulations for the Implementation of Drug Administration Law of the People's Republic of China (hereinafter referred to as Regulations for the Implementation of Drug Administration Law) and other regulations related to supervision on advertisements and drugs.

Article 2 A drug advertisement refers to any advertisement published through various media or forms containing drug name, indications (functions) or other relevant contents, and shall be examined and approved in accordance with the Provisions.

Where only the names of non-prescription drugs (including adopted names and trade names) are publicized or only the names of prescription drugs (including adopted names and trade names) are publicized in professional medical or pharmaceutical journals, the examination is not required.

Article 3 The drug advertisement applied for examination shall be approved provided that it conforms to the following laws, regulations and related provisions:
(1) Advertisement Law;
(2) Drug Administration Law;
(3) Regulations for Implementation of Drug Administration Law;
(4) Criteria for Examining and Publishing Drug Advertisement;
(5) Other provisions of the State on advertisement regulation.

Article 4 The drug regulatory departments of the provinces, autonomous regions or municipalities directly under the Central Government are the drug advertisement examination authorities responsible for examining drug advertisements within their administrative regions. The administrative departments for industry and commerce at or above the county level are supervision and control authorities for drug advertisements.

Article 5 The State Food and Drug Administration shall guide and supervise the examination conducted by drug advertisement examination authorities and punish, in accordance with law, the examination authorities that have violated the Provisions.

Article 6 An applicant for a drug advertisement approval number must be an eligible drug manufacturer or distributor. Where the applicant is a drug distributor, the consent of the drug manufacturer is required.

An applicant may entrust an agent with the application for a drug advertisement approval number.

Article 7 An application for a drug advertisement approval number shall be submitted to the drug advertisement examination authority in the place where the drug manufacturer is located.

An application for an import drug advertisement approval number shall be submitted to the drug advertisement examination authority in the place where the agent of the import drug is located.

Article 8 Where a drug manufacturer or distributor applies for a drug advertisement approval number, it shall submit an Application Form for Drug Advertisement (Appendix 1) with sample manuscript (sample film or sample record) of which the content is consistent with that to be published attached, and an electronic document of drug advertisement application. It shall also submit the following proof documents that are authentic, legal and valid:
(1) Copy of the Business License of the applicant;
(2) Copy of the Drug Manufacturing Certificate or the Drug Supply Certificate of the applicant;
(3) Where the applicant is a drug distributor, the original document proving that the drug manufacturer authorizes the drug distributor to be the applicant shall be submitted;
(4) Where an agent submits an application for a drug advertisement approval number on behalf of the applicant, an original authorization letter given by the applicant to the agent, a copy of business license of the agent and other documents proving the subject’s qualifications shall be submitted;
(5) Copies of the drug approval document (including Import Drug License or Pharmaceutical Product License), copy of approved insert sheet, and label and insert sheet used in practice;
(6) For non-prescription drug advertisement, a copy of registration certificate of non-prescription drug examination or copies of relevant certificates is required;
(7) Where an applicant applies for an import drug advertisement approval number, copies of qualification certificates of the agent of the import drug shall be submitted;
(8) Where the trade name, registered trademark and patent of the drug are involved in an advertisement, copies of the valid certificates and other relevant documents proving the authenticity of the advertisement shall be submitted.

The copy of any approval document prescribed in this Article shall be sealed by the document holder.

Article 9 An advertisement application by an enterprise for a drug shall not be accepted by the drug advertisement examination authorities under any of the following circumstances:
(1) Any of the circumstances under which the application shall be rejected as prescribed in Article 20, Article 22 and Article 23 of the Provisions;
(2) An administrative procedure to withdraw a drug advertisement approval number is in process.

Article 10 After receiving an application for drug advertisement approval number, where the dossier is complete and in conformity with statutory requirements, the drug advertisement examination authority shall issue an Acceptance Notice of Drug Advertisement; where the dossier is incomplete or not conforming to the statutory requirements, one notification on all the content to be supplemented or corrected shall be given to the applicant on the spot or within five working days; if the notification to the applicant is not issued within the timeline, the application is deemed as being accepted upon the date when the dossier is received.

Article 11 Within ten working days upon accepting an application, the drug advertisement examination authority shall check the authenticity, legality and validity of the documents submitted by the applicant, and shall examine the advertisement content in accordance with law. For the drug advertisement in conformity with statutory requirements, a drug advertisement approval number shall be issued; for those not in conformity with statutory requirements, the authority shall make a decision of not issuing a drug advertisement approval number and notify the applicant of the decision with reasons in written form and the applicant’s right to apply for administrative reconsideration or to bring an administrative suit by law.

For approved drug advertisement, the drug advertisement examination authority shall report to the State Food and Drug Administration for records and send the approved Application Form for Drug Advertisement to the authority responsible for advertisement supervision and control at the same level for records. Where there is any problem in the drug advertisement reported to the State Food and Drug Administration for records, the State Food and Drug Administration shall instruct the drug advertisement examination authority to correct it.

The drug regulatory departments shall announce the approved drug advertisement timely.

Article 12 Where a drug advertisement is to be published in the province, autonomous region or municipality directly under the Central Government other than the place where the drug manufacturer and the agent of the import drug are located (hereinafter referred to as “non-local drug advertisement”), it shall, before being published, be submitted for records to the drug advertisement examination authority in the place where the advertisement is to be published.

Article 13 The following materials for non-local drug advertisement shall be submitted for record:
(1) Copy of the Application Form for Drug Advertisement;
(2) Copy of the approved drug insert sheet;
(3) For television or audio broadcast advertisement, it is required to submit the audio tape, compact disc or other medium carrier on which the content is consistent with the approved content.

The copy of any document prescribed in this Article shall be sealed by the document holder.

Article 14 For application for putting non-local drug advertisement on record in accordance with Articles 12 and Article 13 of the Provisions, the drug advertisement examination authority shall, within five working days after accepting the application, put such drug advertisement on record, endorse the word “recorded” on the Application Form for Drug Advertisement, affix the seal specific for drug advertisement examination and send the form to the supervision and control authorities for advertisements at the same level for future reference.

Where the drug advertisement examination authority of a place where a drug advertisement is to be put on record finds that the drug advertisement is not conformed with the relevant provisions, it shall fill in the Opinion on the Record of Drug Advertisement Examination (Appendix 2), submit it to the original drug advertisement examination authority for check, and copy it to the State Food and Drug Administration.

Within five working days upon receiving the Opinion on the Record of Drug Advertisement Examination, the original drug advertisement examination authority shall give its opinions to the drug advertisement examination authority of the place where the drug advertisement is to be put on record. Where no consensus is achieved between the original drug advertisement examination authority and the drug advertisement examination authority of the place where a drug advertisement is to be put on record, the case may be submitted to the State Food and Drug Administration that shall make a final judgment.

Article 15 The valid term of a drug advertisement approval number is one year. It shall become invalid upon expiration.

Article 16 The content of an approved drug advertisement is not allowed to be changed when being published. Where any change to the drug advertisement is needed, a new drug advertisement approval number shall be obtained.

Article 17 Where an advertisement applicant publishes a drug advertisement by itself, it shall keep the original Application Form for Drug Advertisement for two years for future check.

Where an advertisement publisher or advertising operator is authorized by the applicant to publish a drug advertisement, it shall check the original Application Form for Drug Advertisement, publish the advertisement in accordance with the approved content and keep a copy of the Applicant Form for Drug Advertisement for two years for future check.

Article 18 Where there is any of the following circumstances for an approved drug advertisement, the original drug advertisement examination authority shall issue a Notice of Drug Advertisement Re-examination (Appendix 3) and conduct the re-examination. The drug advertisement may continue to be published during the re-examination.

(1) The State Food and Drug Administration finds that the content of the drug advertisement approved by the drug advertisement examination authority is not in conformity with the provisions;
(2) A supervision and control authority for advertisement at or above provincial level makes a re-examination proposal;
(3) Other circumstances where a re-examination is required by a drug advertisement examination authority.

After re-examination, where the drug advertisement is not in conformity to the statutory requirements, the Application Form for Drug Advertisement shall be taken back and the original drug advertisement approval number shall become invalid.

Article 19 Drug advertisement examination authorities shall cancel the drug advertisement approval number in any of the following circumstances:
(1) Where a Drug Manufacturing Certificate or the Drug Supply Certificate is revoked;
(2) Where a drug approval document is withdrawn or cancelled;
(3) Where the State Food and Drug Administration or the drug regulatory department of the province, autonomous region or municipality directly under the Central Government instructs to stop the production, sales and use of the drug.

Article 20 For any alteration to the approved content of a drug advertisement for false propaganda, the drug regulatory departments shall instruct to stop the publication of the advertisement immediately, revoke the drug advertisement approval number, and shall not accept any application for advertisement of the drug within one year.

Article 21 Where any illegal advertisement in which the scope of indications (functions) of the drug is expanded without authorization, the therapeutic effectiveness is exaggerated extremely, or which seriously cheats or misleads the customers, is found, the drug regulatory department at or above the provincial level shall take mandatory administrative measures to suspend the sales of the drug within their administrative area and order the enterprise that illegally publishes the drug advertisement to issue a correction notice in relevant local media.

After the enterprise that illegally publishes the drug advertisement issues a correction notice as required, the drug regulatory department at or above the provincial level shall make a decision on lifting the mandatory administrative measures within 15 working days; where it is necessary to test the drug, the drug regulatory departments shall determine whether to lift the mandatory administrative measures within 15 days as from the day when the test report is issued.

Article 22 Where a drug advertisement application providing false materials is found by the drug advertisement examination authority during the examination, no further application of the enterprise in respect of the advertisement of the drug shall be accepted within one year.

Article 23 Where a drug advertisement with an approval number is found by the drug advertisement examination authority to have provided false materials, such drug advertisement approval number shall be revoked and no further application from the enterprise in respect of the advertisement of the drug shall be accepted within three years.

Article 24 Any drug advertisement, of which the approval number is taken back, cancelled or revoked in accordance with Article 18, Article 19, Article 20 and Article 23 of the Provisions, shall be discontinued for publication immediately; non-local drug advertisement examination authorities shall stop filing the record of the advertisement of the enterprise with the drug advertisement approval number.

Where a drug advertisement examination authority takes back, cancels or withdraws a drug advertisement approval number in accordance with Article 18, Article 19, Article 20 and Article 23 of the Provisions, it shall notify the supervision and control authority for advertisements at the same level within five working days from the day when the administrative decision on the matter is made; the supervision and control authority for advertisements shall handle it in accordance with law.

Article 25 Where a non-local drug advertisement is found not put on record in the drug advertisement examination authority of the place where it is published, the authority shall instruct to file its record within a time limit. If the record is not filed within the time limit, the drug advertisement in the above-mentioned place shall be suspended.

Article 26 The drug regulatory department at or above the county level shall monitor and check the publishing of drug advertisement that has been examined and approved. For any illegal drug advertisements, drug regulatory departments at all levels shall fill in the Notice on the Transfer of Illegal Drug Advertisement (Appendix 4) and transfer it to an supervision and control authority for advertisements at the same level together with such materials as samples of illegal drug advertisement; where the content of approved non-local drug advertisement is altered without permission, the drug advertisement examination authority of the place where the advertisement is published shall advise the original drug advertisement examination authority to revoke its approval number in accordance with Article 92 of the Drug Administration Law and Article 20 of the Provisions.

Article 27 Where an illegal drug advertisement is published and the circumstances are serious, the drug regulatory department of province, autonomous region or municipality directly under the Central Government shall announce the matter to the public and timely report it to the State Food and Drug Administration. The State Food and Drug Administration shall summarize and release the collected information periodically.

Where any false or illegal drug advertisement is published and the circumstances are serious, it shall be announced to the public jointly by the State Administration for Industry and Commerce and the State Food and Drug Administration if necessary.

Article 28 For any drug advertisement published without approval, or the contents published inconsistent with the approved ones, the supervision and control authority for advertisements shall impose a punishment in accordance with Article 43 of the Advertisement Law; where it constitutes false advertisement or misleading propaganda, the supervision and control authorities for advertisements shall impose a punishment in accordance with Article 37 of the Advertisement Law and Article 24 of Anti-Unfair Competitions Law.

In the process of investigation of an illegal drug advertisement, where there is a need to affirm any drug technical information, the supervision and control authority for advertisements shall notify the drug regulatory department at or above the provincial level. The drug regulatory department at or above the provincial level shall give the affirmation result to the supervision and control authorities for advertisements within ten working days after receiving the notification.

Article 29 The staff members that examine and supervise drug advertisements shall be trained in such laws and regulations as the Advertisement Law and the Drug Administration Law. Where the staff members in drug advertisement examination department or in supervision and control authority for drug advertisements neglect their duty, abuse their power, or practice favoritism and commit irregularities, they shall be given an administrative sanction in accordance with law. If a crime is constituted, they shall be investigated for their criminal liabilities in accordance with law.

Article 30 A drug advertisement approval number shall be “X Yao Guang Shen (Shi) No. 0000000000", “X Yao Guang Shen (Sheng) No. 0000000000", “X Yao Guang Shen (Wen) No. 0000000000". “X” is the abbreviation for a province, autonomous region or municipality directly under the Central Government. “0000000000” is a number with ten digits, in which the first six represent year and month of the examination, and the last four represent advertisement approval sequence number. “Shi”, “Sheng” or “Wen” represents certain classification code used in advertising media.

Article 31 These Provisions shall come into force as of May 1, 2007. The Provisions for Drug Advertisement Examination issued by the State Administration for Industry and Commerce and the Ministry of Health (Decree of State Administration for Industry and Commerce No. 25) on March 22, 1995 shall be annulled therefrom.


下载地址: 点击此处下载

聊城市重点建设项目管理办法

山东省聊城市人民政府


聊城市人民政府关于印发《聊城市重点建设项目管理办法》的通知

聊政发〔2011〕17号



各县(市、区)人民政府,经济开发区管委会,市政府各部门:
  《聊城市重点建设项目管理办法》已经市政府第44次常务会议审议通过,现印发给你们,望认真遵照执行。


聊城市人民政府

二○一一年二月二十一日


聊城市重点建设项目管理办法


第一章 总 则

  第一条 为加强对市重点建设项目的管理,确保项目按计划推进实施,加快投资结构调整,提高投资质量和效益,促进全市经济和社会持续、快速、健康发展,依据国家、省有关法律法规和政策规定,结合我市实际,制定本办法。
  第二条 本办法所称重点建设项目,是指符合国家产业政策和发展规划,能够促进产业结构优化升级,能够带动区域经济和行业发展,能够增强全市经济综合实力和社会事业发展的骨干项目。具体包括:
  (一)农林水利、交通、能源等重大基础设施项目;
  (二)推进工业结构调整、节能减排的项目和技术改造项目;
  (三)带动行业技术进步、促进产业升级的战略性新兴产业和高新技术项目;
  (四)教育、文化、卫生、体育、城建设施等重大社会民生项目;
  (五)旅游、现代物流、创新服务等重大现代服务业项目;
  (六)利用外资规模较大的项目。
  第三条 重点建设项目按阶段分为年度重点建设项目和重点推进前期工作项目。
  (一)年度重点建设项目是指当年列入全市100个年内计划新开工和结转的重点建设项目。
  (二)重点推进前期工作项目(以下简称重点推进项目)是指符合市重点建设项目标准,已完成市场考察论证,但尚不具备开工条件,拟于未来二至三年内开工建设的项目。
第二章 申报与确定
  第四条 重点建设项目申报程序。市重点建设项目原则上每年确定一次,市发改委组织筛选、汇总并提出初步意见,报市政府研究确定。
  (一)各县(市、区)政府、经济开发区管委会和市政府有关部门,根据项目的属地原则及隶属关系,按照重点项目筛选的范围和要求,组织筛选本区域、本系统内的重点项目,并于每年11月底前向市发改委提报列入下一年度的市重点建设项目申请。
  (二)市发改委根据各县(市、区)、经济开发区和市直有关部门的申请进行审核,在征求市经信、住建、规划、国土、环保等有关部门意见的基础上,提出市重点项目建议名单和年度投资计划,报市政府常务会议研究确定。
  第五条 重点建设项目的申报条件。
  (一)年度重点建设项目的申报条件:
  1.申请列入年度重点建设项目必须首先经县(市、区)政府、经济开发区管委会研究确定;
  2.符合国家产业政策,并已基本完成项目立项、土地、规划、环评、节能审查等有关建设手续;
  3.交通、能源和技术改造项目投资规模原则上在1亿元人民币以上;高新技术、服务业、社会民生及其他项目投资规模应在3000万元以上;结转续建的项目必须是当年完成投资5000万元以上。
  (二)重点推进项目的申报条件:
  1.符合国家产业政策,具有前瞻性,能够对地方乃至全市经济和社会发展起到拉动作用的项目;
  2.交通、能源和技术改造项目投资规模应在5亿元以上;高新技术、服务业、社会民生及其他项目投资规模应在1亿元以上。
第三章 管 理
  第六条 市发改、经信、住建、监察、财政、国土、环保、交通、水利等有关部门,各县(市、区)人民政府、经济开发区管委会要在各自的职责范围内对重点建设项目实施监督管理。
  (一)成立市重点建设项目领导小组,领导小组下设办公室,办公室设在市发改委,同市重大项目办公室一个机构,两个牌子,统管全市重点项目的筛选和建设工作。主要包括指导、检查和督促全市重点项目建设,分析市重点项目运行动态,检查重点项目计划执行情况,协调解决重点项目实施过程中遇到的问题,对难以解决的重大问题,提出意见和建议。
  (二)各县(市、区)人民政府、经济开发区管委会及其有关业务管理部门具体负责本区域内和业务管理范围内重点项目的建设实施,协调项目建设的资金、征地、拆迁等有关事项,保证重点建设项目顺利建设。
  (三)项目法人单位是重点建设项目的第一责任人,对重点建设项目前期手续、施工进度、安全、质量、投资效益等全面负责,并依法承担相应的经济和法律责任。
  第七条 重点建设项目实行市、县领导帮包制、项目法人责任制。市级帮包领导要定期到项目单位和企业了解项目建设进展情况,帮助协调解决项目建设中的问题,督促项目建设进度;县级帮包领导要随时指导项目建设,参与项目工程计划的制定,监管项目的实施;项目法人具体负责项目的筹建,施工进度,建设质量等,并定期向市、县帮包领导汇报项目建设进展情况和工程建设中遇到的问题。
  第八条 重点建设项目管理,实行月调度、季分析、半年观摩检查、年终全面考核制度,项目建设进展情况,每季度在聊城日报和电视台进行公布。市、县发改部门负责项目的调度、汇总、分析工作,市政府进行项目进展情况的季通报和组织半年观摩检查,市委、市政府进行年终全面考核。县(市、区)发改部门、重点建设项目的项目法人应当按照有关规定,指定专人负责重点建设项目完成情况的统计上报,每月3日前,报送上月的项目资金到位、完成投资、工程形象进度和存在问题及下月工作计划。市发改委汇总后,每月15日前报送市委、市政府主要负责人。
  第九条 重点项目建设应严格执行固定资产投资管理程序,按照国家规定履行各类报批或审核手续,完成项目立项、环评、土地使用、规划许可、节能评估等开工前的各项必要条件。严禁未批先建或边勘察、边设计、边施工的“三边”工程。
  第十条 市重点建设项目的勘察、设计、施工、监理、重要设备和材料采购,应当依法进行公开招标,择优选定中标单位;不适宜公开招标的,经市发改、财政部门同意,报经市政府批准后,可采取邀请招标或竞争性谈判等采购形式。
  第十一条 重点建设项目建成并经过试运营后,重点建设项目单位依据有关规定及时申请有关单位进行验收。
第四章 保 障
  第十二条 任何单位和个人不得扰乱重点项目建设、生产经营秩序。重点建设项目单位,有权拒绝未经物价、财政部门批准的各种不合理收费。
  第十三条 各有关部门要加大对重点项目的支持力度,电力、交通、电信、供水、供热、供气等单位,应当优先保证市重点建设项目施工生产用电、物资运输、通信和用水、用热、用气等方面的需要,按照合同的约定履行义务。各级国土资源管理部门应优先保障市重点建设项目的建设用地,对投资规模大、科技水平高、支持带动性强的项目,用地指标由市优先安排。
  第十四条 根据对重点建设项目资金需求,市政府每年组织召开一次项目银企对接会议,确保全市及市外商业银行最大限度支持重点项目建设。市、县有关部门对重点项目要给予重点倾斜和支持,特别是在申报争取上级扶持资金时要优先考虑。
  人民银行聊城支行和市银监局要加强指导,鼓励和引导各商业银行贷款投向重点建设项目。
第五章 考核与奖惩
  第十五条 加强对县(市、区)的考核,将市重点建设项目的个数、年度完成投资总量、完成年度计划比重、项目投资结构等情况作为对各县(市、区)、经济开发区年度考核的重要单项内容,进行考核。对考核前三名的县(市、区),在全市年度经济综合考核中给予适当加分,并进行表彰奖励;对考核末位的县(市、区),当年不得评为全市年度经济综合考核前三名。
  第十六条 加强对部门的考核,对参与帮包项目的市直部门,主要考核部门帮包项目实施进度、帮助协调解决问题效果等;对没有帮包项目的市直部门,主要考核部门为项目建设提供服务效果等,同时,市级帮包领导将对有关部门进行评议。依据考核结果,对工作好的部门,在全市年度经济综合考核中给予适当加分,并进行表彰奖励。对重点项目建设服务不到位,影响重点项目建设进度的部门和单位,要追究相关人员的责任,并通报批评;对故意设置障碍,使重点项目建设造成重大损失的部门和单位,要依法追究有关人员的责任,并取消当年评先评优资格。
  第十七条 项目建设单位应严格按照市委、市政府下达项目建设任务,加快项目建设进度,保障项目按期完成。对按计划建设实施,施工管理规范的前十名企业进行表彰奖励。对管理不善,造成工期拖延、概算失控、质量低劣和损失浪费严重的,有关部门依法依纪给予有关责任人员严肃处分;出现安全事故的给予一票否决。
第六章 附 则
  第十八条 本办法自2011年3月1日起实施。
  第十九条 本办法由市发改委负责解释。  




吉林省人民政府办公厅关于印发吉林省合作金融机构风险防范处置方案的通知

吉林省人民政府办公厅


吉林省人民政府办公厅关于印发吉林省合作金融机构风险防范处置方案的通知

吉政办发[2003]76号


各市州、县(市、区)人民政府,省政府各厅委、各直属机构:

按照国务院关于深化农村信用社改革试点工作的总体部署,为了切实防范金融风险,保证农村信用社改革试点工作的顺利进行,省农村信用社改革工作领导小组经过认真研究,制定了《吉林省合作金融机构风险防范处置方案》。经省政府同意,现印发给你们,请认真组织贯彻落实。


吉林省人民政府办公厅
二○○三年十二月三十一日



吉林省合作金融机构风险防范处置方案



(省农村信用社改革工作领导小组 二○○三年十一月十日)


为认真贯彻落实《国务院关于印发深化农村信用社改革试点方案的通知》(国发[2003〕15号)精神,切实有效地防范我省合作金融机构可能出现的风险,特制定本方案。

一、指导思想

全省各级政府及各地合作金融机构,要本着“一手抓改革、一手抓行业管理”的指导思想开展工作,努力防范和化解合作金融机构可能出现的金融风险,确保我省合作金融机构平稳健康运行。

二、组织领导

为防范和处置改革期间可能发生的金融风险,省政府成立风险防范处置工作领导小组:

组 长:高继泰(省政府副秘书长)

副组长:佟 钢(省政府金融办主任)

王洪志(省银监局副局长)

付 裕(人民银行长春中心支行副行长)

成 员:唐忠民(省政府金融办副主任)张晓华(长春市政府副秘书长)张文才(吉林市政府副秘书长)贾庆和(四平市政府副秘书长)张 枫(辽源市政府副秘书长)梁 斌(通化市政府副秘书长)王 玉(白山市政府副秘书长)黄真久(白城市政府副秘书长)崔成一(延边州政府副秘书长)刘晓兰(人民银行长春中心支行货币信贷处处长)钱 宏(省银监局合作处处长)李永祥(省银监局信合办主任)领导小组下设办公室,办公室设在省政府金融办。联系电话:0431-8904386。

各级政府要成立相应的风险防范和处置工作领导小组。

三、风险防范

(一)建立支付预警机制。密切关注合作金融方面的社会舆论,对社会上可能出现的不利言论和行为,要注意引导,妥善处理;对恶意、影响大的,当地政府要及时加以制止。加强与银监会派出机构、合作金融机构联系,强化对支付状况监测,准确掌握风险信息,尽早发现风险苗头,及时发出预警报告。(二)建立突发性支付风险应急处理机制。尽快制定当地合作金融风险防范和处置预案,明确启动条件,规定实施程序,并做好预案随时启动的各项准备工作。(三)银监会各级派出机构要加强金融监管,密切关注本地区合作金融机构潜在的各类风险,遇有风险及时按程序报告。(四)各级农村信用联社要立即建立和完善风险防范处置工作制度。一是要对所辖信用风险情况定期进行排查,早发现,早处理。二是要建立风险报告制度。高风险社要将风险情况在每月初上报县(市、区)联社,对突发性的风险情况必须随时上报上级联社和当地政府,不得超过6小时;各县(市、区)联社要于每月中旬将所辖信用社风险情况上报市州联社或省联社派出机构;各市州联社和派出机构要及时向省风险防范和处置工作领导小组报告所辖信用社风险情况并抄报省农村信用社管理机构。三是各级联社和信用社都要建立突发性风险应急处理机制,先期预见,未雨绸缪。四是对高风险信用社要做好资金头寸匡算,掌握资金缺口。五是对发生的各类案件要按照轻重程度及时逐级上报。

四、风险处置

对信用社出现的支付风险,各级政府要及时启动处置预案。对发生支付困难的合作金融机构,其各级联社要首先组织辖区机构进行同业支救,通过资金调剂,帮助度过难关;在同业支救不足以平抑支付风险的情况下,其各级联社要及时向当地人民银行提出动用存款准备金申请;对同业支救、动用存款准备金仍不能解决问题的,要及时向人民银行提出紧急再贷款申请。各级政府要积极主动地协调各方面的关系,提高救助工作效率。同时,在发生挤提和支付风险等重大情况时,要及时向省政府报告。

五、工作要求

(一)统一领导,提高认识。各级政府和各部门要充分认识金融风险的隐蔽性和传播性,同时要确保在省政府风险防范和处置工作领导小组的直接领导下开展工作。(二)分工负责,密切配合。各级政府和各部门要分工负责,密切配合,确保辖区合作金融机构安全稳健运行。(三)深入实际,扎实工作。各级政府和各部门要深入各级合作金融机构,全面掌握各级合作金融机构的实际情况,客观反映实际问题,把工作落到实处。